Gemma Marceniuk
5 Papers
1 Citations
Gemma Marceniuk is an academic researcher. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke: a systematic review and economic evaluation.
TL;DR: The results indicate that implantable cardiac monitors could be considered cost-effective at a £20,000-30,000 threshold, and a two-stage de novo economic model was developed that captured the lifetime costs and benefits of patients on either anticoagulation or antiplatelet treatment.
23
Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study.
Steven J Edwards,Samantha Barton,Mariana Bacelar,Charlotta Karner,Peter Cain,Victoria Wakefield,Gemma Marceniuk +6 more
TL;DR: In this paper, a de novo economic model was developed to compare the costs and consequences of two treatment approaches -the 'top-down' and'step-up' strategies, with step-up considered standard care - in people at high risk of following a severe course of Crohn's disease.
2
EE309 Impact of Differential Baseline Utility Values: Atopic Dermatitis
TL;DR: In this paper , the authors examined if differing baseline utilities have a meaningful impact in cost-utility analysis (CUA) using atopic dermatitis as an example, and found that imperfect randomisation can lead to differences.
VivaScope® 1500 and 3000 systems for detecting and monitoring skin lesions: a systematic review and economic evaluation.
Steven J Edwards,Ifigeneia Mavranezouli,George Osei-Assibey,Gemma Marceniuk,Victoria Wakefield,C Karner +5 more
TL;DR: VivaScope was also shown to be a dominant strategy when used for the diagnostic assessment of suspected basal cell carcinoma (BCC) and a probabilistic de novo economic model was developed to synthesise the available data on costs and clinical outcomes from the UK NHS perspective.
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
Steven J Edwards,Charlotta Karner,Tracey Jhita,Samantha Barton,Gemma Marceniuk,Zenas Zee Ngai Yiu,Miriam Wittmann +6 more
TL;DR: Network meta-analyses indicate that abrocitinib 200 mg and upadacitinib 30 mg may be more effective, and tralokinumab may be less effective than dupilumab and baricitinib as second-line systemic therapies.